Tesamorelin is a synthesized derivative of the human Growth Hormone Releasing Hormone, created from a 44-amino acid sequence.
In HIV patients with lipodystrophy, the treatment is a synthetic peptide counterpart of the hypothalamic peptide (GHRH), which is designed to reduce fat in the abdomen. Lipodystrophy is a metabolic disorder caused by a combination of insulin resistance, increased fat, and high cholesterol that often develops as a result of anti-HIV drug treatment.
Molecular Weight: 5136 g/mol
What is tesamorelin, and how does it work?
Tesamorelin is a medication that contains growth hormone-releasing factor (GHRF) (GRF).
When subjects are on some HIV medicines, they may develop extra fat around their stomach. Tesamorelin is used to help them lose this fat. Lipodystrophy is a term used to describe this disease (LYE-Poe-DIS-troe-fee). Tesamorelin is not a weight-loss drug and should not be used to treat obesity unless it is clearly indicated.
When used to treat subjects with HIV who have changes in the way their body fat is distributed, tesamorelin may help to decrease the amount of excess fat around their stomach. There is no evidence that tesamorelin can aid in weight reduction, and it should not be used to treat obesity.
The use of Tesamorelin is not recommended for patients who have cancer, a pituitary gland disease or a family history of pituitary gland tumors, a prior head injury or radiation therapy, or if they are presently pregnant.
The underlying mechanism of action
Tesamorelin works by inducing the body to generate more quantities of growth hormone than it would otherwise. In the brain, tesamorelin works on the pituitary cells, increasing the synthesis and release of the endogenous hormone (hGRF). Tesamorelin, by stimulating growth hormone production, also raises the levels of IGF-1 and IGFBP-3 in the bloodstream, which is beneficial.
Symptoms and Consequences
Tesamorelin is generally associated with minor side effects if any at all. However, the following complications may occur: Redness, irritation, discomfort, and bruising at the injection site, muscular soreness, depression, sleeplessness, rash or itching, night sweats, nausea, and/or vomiting are all possible side effects of this medication.
Tesamorelin has the potential to induce birth abnormalities or damage an unborn child. The procedure should not be performed if the patient is pregnant.
It is not recommended that subjects be given tesamorelin if they are allergic to it, or if they have a history of tumor or surgery of their pituitary gland, a history of head injury or radiation therapy, or if they have any other medical conditions that may prevent them from receiving it.
It is important for the researcher to be aware of any heart illness, high blood pressure, kidney disease, diabetes, epilepsy (including migraines), an adrenal gland problem, or if the patient has ever had cancer, any kind of tumor, or open-heart surgery before administering tesamorelin to them.
Natural human growth hormone synthesis is being increased.
An increase in IGF-1 and IGFBP-3 levels has been seen.
Triglyceride levels are being brought down.
Protein synthesis is being increased.
Visceral adipose tissue has decreased in size.
Adults over the age of 60 who have improved in their cognitive
c-reactive protein (CRP) reduction
Abdominal fat is being reduced.
If you are a licensed researcher who is interested in further investigating the potential of this peptide, you can buy Tesamorelin online.